← Leaderboards
Raymond C Bergan
University Of Nebraska Medical Center
$7,632,509
Attributed
$9,096,785
Total exposure
12
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.7M · FY2006–25$2M$1.5M$1M$500K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,096,785 · 11
VA$0 · 1
By mechanism
R01$4,491,988 · 2
N01$2,397,342 · 3
P50$1,223,928 · 3
R21$743,750 · 1
P30$239,777 · 1
I01$0 · 1
Top collaborators
- Amarnath Natarajan5 shared
Most similar at University Of Nebraska Medical Center
Same institution · by research overlap
- Michael A Hollingsworth$34,707,253
- Julia Bridge$3,097,755
- Fenghai Duan$1,728,996
- Larisa Y Poluektova$9,010,153
- Anna Simon$660,000
Others in their field
Top investigators on “Molecular”
- David Heimbrook · Leidos Biomedical Research, Inc.$871,088,761
- Leonard Freedman · Leidos Biomedical Research, Inc.$468,573,385
- Richard Webby · St. Jude Children'S Research Hospital$254,843,170
- Larry Arthur$238,531,074
- Gregory H Reaman · National Childhood Cancer Foundation$230,630,913
- Ralph Parchment · Leidos Biomedical Research, Inc.$193,231,914
Research focus
MolecularProstateNeoplasm MetastasisCancer CellPathway InteractionsDesignLinkMalignant NeoplasmsProgramsBaseMalignant Neoplasm Of ProstateResearch PersonnelClinical ResearchSignal TransductionCell MotilityCarcinogenesisCellsAffectRegulatory PathwayBiologicalTreatment EfficacyFundingMemberGenistein
Grant awards (38)
Preventing invasive prostate cancer$1,607,348
R01 · FY2025 · CA · contact PI
Preventing invasive prostate cancer$138,214
R01 · FY2025 · CA · contact PI
Preventing invasive prostate cancer$508,994
R01 · FY2024 · CA · contact PI
Regulation of extracellular proteases in prostate cancer progression to a metastatic phenotype$138,214
R01 · FY2024 · CA · contact PI
Preventing invasive prostate cancer$535,783
R01 · FY2023 · CA · contact PI
Translational Oncology$4,726
P30 · FY2021 · CA · contact PI
Translational Oncology$36,416
P30 · FY2020 · CA · contact PI
Translational Oncology$52,914
P30 · FY2019 · CA · contact PI
Therapeutically targeting cancer cell motility$0
I01 · FY2019 · VA · contact PI
Translational Oncology$52,914
P30 · FY2018 · CA · contact PI
Translational Oncology$16,564
P30 · FY2018 · CA · contact PI
Translational Oncology$14,999
P30 · FY2018 · CA · contact PI
Translational Oncology$8,330
P30 · FY2018 · CA · contact PI
Therapeutically targeting cancer cell motility$0
I01 · FY2018 · VA · contact PI
Career Development Program$87,428
P50 · FY2017 · CA · contact PI
Translational Oncology$52,914
P30 · FY2017 · CA · contact PI
Therapeutically targeting cancer cell motility$0
I01 · FY2017 · VA · contact PI
Career Development Program$81,919
P50 · FY2016 · CA · contact PI
Therapeutically targeting cancer cell motility$0
I01 · FY2016 · VA · contact PI
Career Development Program$85,084
P50 · FY2015 · CA · contact PI
P-4: Modulation of Prostate CA Cell Motility by Chemopreventive Agt Genistein$206,725
P50 · FY2013 · CA · contact PI
Genistein-mediated Regulation of Prostate Cancer Cell Motility$304,521
R01 · FY2012 · CA · contact PI
P-4: Modulation of Prostate CA Cell Motility by Chemopreventive Agt Genistein$148,049
P50 · FY2012 · CA · contact PI
Genistein-mediated Regulation of Prostate Cancer Cell Motility$304,503
R01 · FY2011 · CA · contact PI
P-4: Modulation of Prostate CA Cell Motility by Chemopreventive Agt Genistein$201,075
P50 · FY2011 · CA · contact PI
Genistein-mediated Regulation of Prostate Cancer Cell Motility$313,904
R01 · FY2010 · CA · contact PI
P-4: Modulation of Prostate CA Cell Motility by Chemopreventive Agt Genistein$198,605
P50 · FY2010 · CA · contact PI
Genistein-mediated Regulation of Prostate Cancer Cell Motility$319,357
R01 · FY2009 · CA · contact PI
Modulation of Prostate Cancer Cell Motility by Chemopreventive Agent Genistein$215,043
P50 · FY2009 · CA · contact PI
Genistein-mediated Regulation of Prostate Cancer Cell Motility$321,150
R01 · FY2008 · CA · contact PI
PHASE 1 AND PHASE 2 CLINICAL TRIALS OF CANCER CHEMOPREVENTIVE AGENTS$1,602,000
N01 · FY2007 · CA · contact PI
PHASE 1 AND PHASE 2 CLINICAL TRIALS OF CANCER CHEMOPREVENTIVE AGENTS-2-261035157$0
N01 · FY2006 · CN · contact PI
Molecular Correlates of Soy in Humans$371,250
R21 · FY2003 · CA
Molecular Correlates of Soy in Humans$372,500
R21 · FY2002 · CA
CORE--CLINICAL RESEARCH$0
P50 · FY2002 · CA
PHARMACOKINETICS OF GENISTEIN, TYROSINE KINASE INHIBITOR$0
M01 · FY2001 · RR
PHASE I MULTIPLE DOSE STUDY OF OLTIPRAZ IN SMOKERS - WOR$795,342
N01 · FY2000 · CN
PHARMACOKINETICS OF GENISTEIN, TYROSINE KINASE INHIBITOR$0
M01 · FY2000 · RR